112 related articles for article (PubMed ID: 546864)
1. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
van der Merwe PJ; Müller DG; Clark EC
J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
[No Abstract] [Full Text] [Related]
2. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
Foukaridis GN
Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
[TBL] [Abstract][Full Text] [Related]
3. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
Neurath GB; Ambrosius D
J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
[No Abstract] [Full Text] [Related]
4. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
5. Spironolactone response related to plasma canrenone concentration [proceedings].
Hettiarachchi J; Ramsay LE
Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
[No Abstract] [Full Text] [Related]
6. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.
Phelps DL; Karim A
J Pharm Sci; 1977 Aug; 66(8):1203. PubMed ID: 894512
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
Merkus FW; Overdiek JW; Cilissen J; Zuidema J
Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
[No Abstract] [Full Text] [Related]
8. Elimination of canrenone in congestive heart failure and chronic liver disease.
Jackson L; Branch R; Levine D; Ramsay L
Eur J Clin Pharmacol; 1977 Mar; 11(3):177-9. PubMed ID: 852495
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
Vergin H; Nuss U; Strobel K
Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
[TBL] [Abstract][Full Text] [Related]
10. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
Ho PC; Bourne DW; Triggs EJ; Smithurst BA
Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
[TBL] [Abstract][Full Text] [Related]
11. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Karim A; Zagarella J; Hutsell TC; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
[TBL] [Abstract][Full Text] [Related]
13. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of HPTLC and green HPLC methods for determination of furosemide, spironolactone and canrenone, in pure forms, tablets and spiked human plasma.
Naguib IA; Abdelaleem EA; Emam AA; Ali NW; Abdallah FF
Biomed Chromatogr; 2018 Oct; 32(10):e4304. PubMed ID: 29855049
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone plasma radioimmunoassay interference by a spirolactone metabolite.
Sadée W; Finn AM; Schmiedek P; Baethmann A
Steroids; 1975 Mar; 25(3):301-11. PubMed ID: 1145668
[TBL] [Abstract][Full Text] [Related]
16. Is canrenone the major metabolite of spironolactone?
Merkus FW
Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
[No Abstract] [Full Text] [Related]
17. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Krause W; Karras J; Jakobs U
J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
[TBL] [Abstract][Full Text] [Related]
18. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
Datta P; Dasgupta A
Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of spironolactone and its active metabolite canrenone in human plasma by HPLC-APCI-MS.
Dong H; Xu F; Zhang Z; Tian Y; Chen Y
J Mass Spectrom; 2006 Apr; 41(4):477-86. PubMed ID: 16541392
[TBL] [Abstract][Full Text] [Related]
20. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
Dasgupta A; Tso G; Wells A
Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
